Some promising new therapeutics have been developed and tested clinically by small groups and companies throughout the world. Pyronaridine was first developed in China. Pyronaridine was concluded to be very effective in P. vivax and P. falciparum malaria and well tolerated. It is highly efficacious in Africa, where chloroquine resistance is well established. Pyronaridine is also found to treat P. ovale and P. malariae in 4 days.
Limitations here is the lack of established pharmacokinetic and problem with recrudescence.
Pyronaridine adopts the quinine moiety and so resistance to it will become inevitable. The biggest issue was that the pharmaceutical giants were not interested and it is too expensive. It is a long acting primaquine analogue. In areas of high infection, primary Health care is usually lacking, familiarity of symptoms and self-diagnosis is quiet common. Anti-malarials are usually purchase in the open market where there is little or no control.